Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

Energy equipment and services provider Flowco launched the year’s first major IPO, planning to raise $392 million and list in ...

Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...

Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S.

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for ...